Emergent BioSolutions said Thursday it will resume manufacturing bulk drug substances for Johnson & Johnson’s COVID-19 vaccine after an extensive review prompted by the ruining of millions of doses at one of its plants.
July 29 (UPI) — Emergent BioSolutions said Thursday it will resume manufacturing bulk drug substances for Johnson & Johnson’s COVID-19 vaccine after an extensive review prompted by the ruining of millions of doses at one of its plants. The company said it was working with the U.S. Food and Drug Administration and Johnson & Johnson to address quality concerns. In April, the FDA asked the company to halt production of materials at its Baltimore facility for COVID-19 vaccines after a mix-up of ingredients for Johnson & Johnson’s vaccine and AstraZeneca’s.
